Assessing the appropriateness of combining economic data from multinational clinical trials

Statistics in Medicine

Volumn 22, Issue 12, 2003, Pages 1955-1976

  Cook, John R ^a   Drummond, Michael ^b   Glick, Henry ^c   Heyse, Joseph F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cost effectiveness; Interaction; Multinational clinical trials; Net health benefits

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; PLACEBO; SIMVASTATIN;

ANALYTIC METHOD; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DENMARK; DRUG COST; ECONOMIC EVALUATION; FINLAND; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEART INFARCTION; HOSPITAL COST; HUMAN; ICELAND; INFORMATION PROCESSING; MEDICAL ASSESSMENT; MORTALITY; NORWAY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCANDINAVIA; SURVIVAL; SWEDEN;

ANTICHOLESTEREMIC AGENTS; DATA INTERPRETATION, STATISTICAL; HEALTH CARE COSTS; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; SCANDINAVIA; SIMVASTATIN;

EID: 0038543516     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1389     Document Type: Article

References (37)

1. Adams ME, McCall NT, Gray NT, Orza MJ, Chalmers TC. Economic analysis in randomized control trials. Medical Care 1992; 30:231-243.
2. Drummond MF, Davies LM. Economic analysis alongside clinical trials: revisiting the methodological principles. International Journal of Technology Assessment in Health Care 1991; 7:561-573.
3. Glick H. Strategies for economic assessment during the development of new drugs. Drug Information Journal 1995; 29:1391-1403.
4. Schulman KA, Buxton M, Glick H, Sculpher M, Guzman G, Kong J, Backhouse M, Mauskopf J, Bell L, Eisenberg JM and the FIRST Investigators. Results of the economic evaluation of the FIRST study: a multinational prospective economic evaluation. International Journal of Technology Assessment in Health Care 1996; 12:698-713.
5. Mark DB, Flatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight D, Harrell FE, Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. New England Journal of Medicine 1995; 332:1418-1424.
6. Schulman KA, Glick H, Buxton M, Sculpher M, Backhouse M, Bell L, Eisenberg JM. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Controlled Clinical Trials 1996; 17:304-315.
7. Glick H, Wilke R, Polsky D, Llana T, Alves WM, Kassell N, Schulman K. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: economic evaluation of a phase III clinical trial in Europe and Australia. International Journal of Technology Assessment 1998; 14:145-160.
8. Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Jones RP de Pouvourville G, Torfs K. Issues in the cross-national assessment of health technology. International Journal of Technology Assessment in Health Care 1992; 8:671-682.
9. O'Brien BS. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. American Journal of Managed Care 1997; 3(supplement):S33-S40.
10. Hull RD, Hirsh J, Sackett DL, Stoddart GL. Cost-effectiveness of clinical diagnosis, venography and non-invasive testing in patients with symptomatic deep-vein thrombosis. New England Journal of Medicine 1981; 304:1561-1567.
11. Wilke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Economics 1998; 7:481-493.
12. Stucki G, Johannesson M, Liang MH. Use of misoprostol in the elderly: is the expense justified? Drugs and Aging 1996; 8:84-88.
13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334:1383-1389.
14. FASS. Lakemedel i Sverige. Lakemedelsinformation AB: Stockholm, Sweden, 1995.
15. SPRI. DRG vid Kungalvs sjukhus. SPRI rapport 395. SPRI: Stockholm, Sweden, 1995.
16. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H for the Scandinavian Simvastatin Survival Study Group. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal 1996; 17:1001-1007.
17. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. New England Journal of Medicine 1997; 336:332-336.
18. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyorala K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jonsson B, Schwartz JS for the Scandinavian Simvastatin Survival Study Group. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996,- 93:1796-1802.
19. Fleiss JL. Analysis of the data from multiclinic trials. Controlled Clinical Trials 1986; 7:267-275.
20. Ciminera JL, Heyse JF, Hguyen HH, Tukey JW. Evaluation of multicenter clinical trial data using adaptions of the Mostellar-Tukey Procedure. Statistics in Medicine 1994; 12:1047-1061.
21. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41:361-372.
22. Peto R. Statistical aspects of cancer trials. In Treatment of Cancer, Halnan KE (ed.). Chapman and Hall: London, 1982; 867-871.
23. Piantadosi S, Gail MH. A comparison of the power of two tests for qualitative interactions. Statistics in Medicine 1993; 12.1239-1248.
24. Pan G, Wolfe DA. Test for qualitative interaction of clinical significance. Statistics in Medicine 1997; 16: 1645-1652.
25. Fenn P, McGuire A, Phillips V, Backhouse M, Jones D. The analysis of censored treatment cost in economic evaluation. Medical Care 1995; 33:851-863.
26. Dudley RA, Harrell FE, Smith LR, Mark DB, Califf RM, Pryor DM, Glower D, Lipscomb G, Hlatky M. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. Journal of Clinical Epidemiology 1993; 46:261-271.
27. Lin DY, Fewer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997; 53:113-128.
28. Cox DR. Regression models and life tables (with discussion). Journal of the Royal Statistical Society, Series B 1972; 34:187-220.
29. Agresti A. An Introduction to Categorical Data Analysis. Wiley: New York, 1996; 80-93.
30. Cook JR, Heyse JF. Use of an angular transformation for ratio estimation in cost-effectiveness analysis. Statistics in Medicine 2000; 19:2989-3003.
31. Chaudhary MA. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996; 15:1447-1458.
32. Mosteller F, Tukey JW. Data Analysis and Regression: A Second Course in Statistics. Addison-Wesley: Reading, MA, 1977.
33. Miller RG. The jack-knife - a review. Biometrika 1974; 61:1-15.
34. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 1998; 18(supplement): S68-S80.
35. Heitian DF. Fieller's method and net health benefits. Health Economics 2000; 9:327-335.
36. Glick HA, Polsky DP, Schulman KA. Trial based economic evaluations: an overview of design and analysis. In Economic Evaluation in Health Care: Merging Theory with Practice, Drummond M, McGuire A (eds). Oxford University Press: Oxford, 2001; 113-140.
37. McGuire A. Theoretical concepts in the economic evaluation of health care. In Economic Evaluation in Health Care: Merging Theory with Practice, Drummond M, McGuire A (eds). Oxford University Press: Oxford, 2001; 1-21.